Event agenda
11th September
Evening – Invitees’ arrival
17:00 – 19:30
J&J Welcome and registration
19:30 – 21:30
Dinner
12th September
09:00 – 09:10
J&J Welcome and Opening
A Connected J&J Oncology Journey
Cristian Benza
1st PANEL
PC
From diagnosis to treatment intensification in advanced prostate cancer
Maria Barbu
09:10 – 09:20
Agenda and Meeting Objectives
09:20 – 10:00
Diagnosis & Staging in Prostate Cancer. Getting the starting point right:
– Pathologist perspective
– Radiologist perspective
Mihai Stoicea
Nina Tunariu
10:00 – 10:10
Interactive Q&A session
10:10 – 10:30
Timing matters: when to intensify in nmCRPC
(Clinical case and scientific evidence)
Nelly Cherciu
10:30 – 10:50
Coffee break
10:50 – 11:20
Personalizing treatment intensification in synchronous mHSPC
(Clinical case and scientific evidence)
Alison Birtle
11:20 – 11:40
Personalizing treatment intensification in metachronous mHSPC
(Clinical case and scientific evidence)
Maria Barbu
11:40 – 12:00
Interactive Q&A session
Closing & remarks
12:00 – 13:00
Lunch
2nd PANEL
PC
Precision medicine in PC: integrating molecular testing (BRCA) to personalize treatment choices
Amedeia Niță
13:00 – 13:20
Why BRCA testing is essential for personalized treatment decisions
Mihai Stoicea
13:20 – 13:50
From guidelines to clinical practice: Personalizing Treatment in BRCA+ mCRPC MAGNITUDE data and guidelines
(Clinical case and scientific evidence)
Adina Nemeș
13:50 – 14:10
From guidelines to clinical practice: Personalizing Treatment in BRCA+ mHSPC AMPLITUDE data and guidelines
(Clinical case and scientific evidence)
Raluca Mihăilă
14:10 – 14:30
Interactive Q&A session
Closing & remarks
3rd PANEL
UC
Targeted therapy in advanced urothelial cancer patients harboring FGFR-alterations and individualizing treatment selection
Amedeia Niță
14:30 – 14:50
Who and when should be tested for FGFR alterations?
Mihai Stoicea
14:50 – 15:10
The role of imaging in advanced urothelial cancer: from accurate staging to treatment decision-making
Nina Tunariu
15:10 – 15:50
Optimizing treatment selection in FGFR+ mUC, clinical evidence from THOR study: how erdafitinib changes expectations for FGFR‑altered patients (clinical case and evidence)
AEs management in urothelial cancer
Alison Birtle
15:50 – 16:00
Interactive Q&A session
Closing & remarks
16:00 – 16:15
Coffee break
4th PANEL
Lung
Advancing Care in EGFRm NSCLC: Evidence, Guidelines, MDT Approach
Laura Mazilu
Michael Schenker
16:15 – 16:25
Scientific Opening – EGFRm NSCLC Landscape
16:25 – 16:45
EGFRm NSCLC with exon 20 insertions: Unmet needs and current guidelines
Michael Schenker
16:45 – 17:05
Rybrevant – Dual Target Precision : The EGFR/MET bispecific mechanism of action
Mircea Dediu
17:05 – 17:15
Interactive Q&A session
17:15 – 17:35
Rybrevant – A new standard of care in EGFRm NSCLC with exon 20 insertions
Laura Mazilu
17:35 – 18:05
Optimizing management of patients with EGFRm NSCLC
Liliana Popa
18:05 – 18:25
Closing & Remarks
19:30 – 21:30
Dinner
13th September
07:00 – 10:00
Breakfast
10:00 – 11:00
Check-out
Johnson&Johnson Romania S.R.L.
Strada Tipografilor nr. 11-15
Clădirea S-Park, Corpul B3, Etaj 3, Camera 1, Corpul B4,
Etaj 3 şi Corp LB, Etaj 3 Sector 1, 013714 Bucureşti,
România
Tel. 021 207 18 00; Fax 021 207 18 11
NU TRANSMITEȚI MAI DEPARTE. Aviz de Confidențialitate: Această comunicare prin poșta electronică (e-mail) poateconține informații confidențiale sau privilegiate legal destinate exclusiv persoanei fizice sau entității numite în adresa de e-mail. Dacă nu sunteți destinatarul de drept, sunteți notificat că orice dezvăluire, copiere, distribuire sau deținere a conținutuluiacestui e-mail este interzisă. Dacă ați primit din greșeală acest e-mail, răspundeți expeditorului (Reply-to) pentru a puteaaranja livrarea corespunzătoare și apoi ștergeți e-mailul.
Mulțumim!
Dacă nu mai doriți să primiți informații din partea noastră prin email, puteți actualiza setările acestui canal mai aici.
CP-596688 | August 2026